See more : Ningbo BaoSi Energy Equipment Co., Ltd. (300441.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Zydus Lifesciences Limited (ZYDUSLIFE.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zydus Lifesciences Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Grupa Zywiec S.A. (ZWC.WA) Income Statement Analysis – Financial Results
- Inventronics Limited (IVX.V) Income Statement Analysis – Financial Results
- Kishin Corporation (092440.KS) Income Statement Analysis – Financial Results
- Virginia Energy Resources Inc. (VUI.V) Income Statement Analysis – Financial Results
- Zhejiang Sanwei Rubber Item Co., Ltd. (603033.SS) Income Statement Analysis – Financial Results
Zydus Lifesciences Limited (ZYDUSLIFE.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.zyduslife.com
About Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 190.22B | 168.78B | 148.28B | 141.25B | 138.12B | 127.48B | 115.81B | 91.67B | 94.27B | 86.51B | 72.24B | 63.58B | 52.63B | 44.65B | 35.74B | 29.28B | 22.66B | 17.86B | 14.45B | 12.43B | 11.96B |
| Cost of Revenue | 65.00B | 65.59B | 58.19B | 50.71B | 51.49B | 49.50B | 43.43B | 36.10B | 32.79B | 33.10B | 28.21B | 24.08B | 17.74B | 14.75B | 11.78B | 9.57B | 7.90B | 6.37B | 5.69B | 4.84B | 5.01B |
| Gross Profit | 125.21B | 103.19B | 90.09B | 90.54B | 86.63B | 77.99B | 72.38B | 55.57B | 61.48B | 53.42B | 44.03B | 39.49B | 34.89B | 29.89B | 23.96B | 19.71B | 14.76B | 11.48B | 8.77B | 7.59B | 6.96B |
| Gross Profit Ratio | 65.83% | 61.14% | 60.76% | 64.10% | 62.72% | 61.17% | 62.50% | 60.62% | 65.22% | 61.74% | 60.95% | 62.12% | 66.29% | 66.95% | 67.03% | 67.32% | 65.12% | 64.31% | 60.64% | 61.06% | 58.14% |
| Research & Development | 13.08B | 1.36B | 1.15B | 1.25B | 897.00M | 1.08B | 1.69B | 1.44B | 1.39B | 1.09B | 574.00M | 823.00M | 571.00M | 2.50B | 1.66B | 1.56B | 1.34B | 1.34B | 797.00M | 736.00M | 615.00M |
| General & Administrative | 5.18B | 5.83B | 4.28B | 4.54B | 5.44B | 3.31B | 2.75B | 2.49B | 2.32B | 1.77B | 1.79B | 1.40B | 1.28B | 18.78B | 15.34B | 12.09B | 1.40B | 926.00M | 707.00M | 665.00M | 703.00M |
| Selling & Marketing | 16.58B | 15.57B | 13.73B | 13.59B | 13.53B | 10.35B | 10.15B | 8.26B | 9.80B | 9.60B | 9.02B | 7.89B | 7.08B | 0.00 | 0.00 | 5.54B | 4.09B | 3.01B | 2.25B | 1.83B | 1.45B |
| SG&A | 21.76B | 21.40B | 18.01B | 18.13B | 18.97B | 13.67B | 12.89B | 10.75B | 12.12B | 11.37B | 10.82B | 9.29B | 8.35B | 18.78B | 15.34B | 12.09B | 5.49B | 3.94B | 2.96B | 2.50B | 2.15B |
| Other Expenses | 101.90B | 36.00M | 31.00M | 22.00M | 84.00M | 81.00M | 46.00M | 78.00M | 131.00M | 92.00M | 28.00M | 24.00M | 35.00M | 0.00 | -46.00M | -241.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 125.21B | 74.64B | 65.32B | 63.17B | 66.06B | 54.67B | 49.38B | 40.30B | 41.06B | 38.53B | 33.92B | 29.98B | 25.37B | 20.77B | 17.05B | 14.57B | 11.04B | 8.52B | 6.63B | 5.85B | 5.10B |
| Cost & Expenses | 149.40B | 140.23B | 123.51B | 113.88B | 117.55B | 104.17B | 92.81B | 76.40B | 73.84B | 71.62B | 62.14B | 54.06B | 43.12B | 35.52B | 28.84B | 24.13B | 18.94B | 14.89B | 12.32B | 10.69B | 10.11B |
| Interest Income | 1.27B | 757.00M | 688.00M | 495.00M | 325.00M | 530.00M | 494.00M | 573.00M | 627.00M | 387.00M | 343.00M | 267.00M | 280.00M | -112.00M | -119.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 492.00M | 1.26B | 1.14B | 1.56B | 3.24B | 1.91B | 1.05B | 568.00M | 410.00M | 555.00M | 1.10B | 1.17B | 1.05B | 587.00M | 702.00M | 1.21B | 413.00M | 223.00M | 251.00M | 245.00M | 210.00M |
| Depreciation & Amortization | 7.64B | 7.23B | 7.13B | 6.70B | 6.97B | 5.99B | 5.39B | 3.73B | 2.92B | 2.87B | 2.01B | 1.85B | 1.58B | 1.27B | 1.34B | 1.12B | 969.00M | 823.00M | 779.00M | 718.00M | 712.00M |
| EBITDA | 56.17B | 34.42B | 36.71B | 32.33B | 25.25B | 31.77B | 29.80B | 20.51B | 24.44B | 18.01B | 12.34B | 11.55B | 11.22B | 10.39B | 8.29B | 6.26B | 4.66B | 3.79B | 2.72B | 2.33B | 2.56B |
| EBITDA Ratio | 29.53% | 23.33% | 23.12% | 24.76% | 20.15% | 23.96% | 25.27% | 21.72% | 25.45% | 20.84% | 17.73% | 17.62% | 20.19% | 23.28% | 23.20% | 21.39% | 20.68% | 21.20% | 20.15% | 19.78% | 21.42% |
| Operating Income | 43.11B | 26.92B | 24.26B | 26.29B | 19.25B | 22.02B | 22.09B | 14.62B | 20.03B | 15.15B | 10.80B | 9.36B | 9.05B | 9.12B | 6.95B | 5.14B | 3.72B | 2.96B | 2.13B | 1.74B | 1.85B |
| Operating Income Ratio | 22.66% | 15.95% | 16.36% | 18.61% | 13.94% | 17.27% | 19.07% | 15.94% | 21.25% | 17.52% | 14.95% | 14.71% | 17.19% | 20.44% | 19.45% | 17.57% | 16.40% | 16.59% | 14.77% | 14.01% | 15.47% |
| Total Other Income/Expenses | 4.98B | -1.02B | 4.12B | -2.30B | -5.61B | 504.00M | 306.00M | 874.00M | 563.00M | -434.00M | -683.00M | -1.43B | -1.57B | -699.00M | -867.00M | -1.45B | -482.00M | -223.00M | -366.00M | -373.00M | -336.00M |
| Income Before Tax | 48.09B | 25.90B | 28.38B | 23.99B | 14.95B | 23.82B | 23.31B | 16.15B | 20.99B | 14.46B | 9.42B | 8.09B | 7.94B | 8.43B | 6.04B | 3.70B | 3.23B | 2.74B | 1.77B | 1.37B | 1.52B |
| Income Before Tax Ratio | 25.28% | 15.34% | 19.14% | 16.99% | 10.83% | 18.69% | 20.13% | 17.61% | 22.26% | 16.71% | 13.04% | 12.72% | 15.09% | 18.87% | 16.90% | 12.63% | 14.27% | 15.34% | 12.23% | 11.03% | 12.67% |
| Income Tax Expense | 9.78B | 5.88B | 5.12B | 1.94B | 3.20B | 5.30B | 5.64B | 1.29B | 1.77B | 2.59B | 1.06B | 1.19B | 1.13B | 1.06B | 741.00M | 666.00M | 613.00M | 324.00M | 243.00M | 192.00M | 213.00M |
| Net Income | 38.60B | 19.60B | 44.87B | 21.34B | 11.77B | 18.49B | 17.76B | 14.88B | 19.34B | 11.49B | 8.04B | 6.54B | 6.53B | 7.11B | 5.05B | 3.03B | 2.58B | 2.34B | 1.52B | 1.20B | 1.33B |
| Net Income Ratio | 20.29% | 11.61% | 30.26% | 15.11% | 8.52% | 14.50% | 15.33% | 16.23% | 20.51% | 13.28% | 11.12% | 10.28% | 12.40% | 15.92% | 14.13% | 10.35% | 11.37% | 13.09% | 10.54% | 9.65% | 11.13% |
| EPS | 38.14 | 19.30 | 17.65 | 20.84 | 11.49 | 18.06 | 17.35 | 14.53 | 18.89 | 11.22 | 7.85 | 6.38 | 6.37 | 6.95 | 4.93 | 2.96 | 2.73 | 2.48 | 1.62 | 2.55 | 2.83 |
| EPS Diluted | 38.14 | 19.30 | 17.65 | 20.84 | 11.49 | 18.06 | 17.35 | 14.53 | 18.89 | 11.22 | 7.85 | 6.38 | 6.37 | 6.95 | 4.93 | 2.96 | 2.73 | 2.48 | 1.62 | 2.55 | 2.83 |
| Weighted Avg Shares Out | 1.01B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 942.10M | 942.10M | 942.10M | 471.05M | 471.05M |
| Weighted Avg Shares Out (Dil) | 1.01B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 942.10M | 942.10M | 942.10M | 471.05M | 471.05M |
Source: https://incomestatements.info
Category: Stock Reports